City of Hope-led trial leads to U.S. Food and Drug Administration’s approval of a first of its kind bispecific antibody

Mosunetuzumab treats people with relapsed or refractory follicular lymphoma, the most common slow-growing form of non-Hodgkin's lymphoma LOS ANGELES, Jan. 5, 2023 /PRNewswire/ -- A trial led by City of Hope, one of the largest cancer research and treatment organizations in the nation,...

Click to view original post